Results of NIH study of asthma in children lead to cautions against short-term high-dose steroid treatment

US researchers have found that a common practice among physicians to increase the use of steroids for worsening symptoms of asthma in children could be linked with slowing a child’s rate of growth. Results of the study found that temporarily increasing the dosage of inhaled steroids when asthma symptoms begin to worsen, not only has

Continue Reading

European Medicines Agency Approves GSK / Theravance’s Relvar

GlaxoSmithKline (GSK) and Theravance’s inhaled lung drug, Relvar, has been approved by Europe’s regulatory body to treat both asthma and chronic obstructive pulmonary disease (COPD). Relvar is a combination of the inhaled corticosteroid fluticasone furoate and the long-acting beta2 agonist (LABA) vilanterol, and is delivered through the Ellipta inhaler.  The drug has already been approved

Continue Reading

Relvar Ellipta Supported by EMA Advisors

Advisors to the European Medicines Agency (EMA) have voted in support of approving GlaxoSmithKline/ Theravance’s Relvar Ellipta for both asthma and chronic obstructive pulmonary disease (COPD). The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has delivered a response recommending marketing authorisation for Relvar Ellipta, a combination of the inhaled corticosteroid fluticasone

Continue Reading

Xolair Endorsement Retracted by NICE

The National Institute for Health and Clinical Excellence (NICE) have released draft guidance withdrawing their recommendation of Novartis’ Xolair for severe persistent allergic asthma. In 2007, NICE circulated guidelines supporting the use of Xolair (omalizumab) on the National Health Service (NHS) for adults whose asthma is poorly controlled.  Then in 2011 they reject the treatment’s

Continue Reading